BioPharmSignal logoBioPharmSignal

Biotech News

Zura Bio to Participate in the Cantor Global Healthcare Conference

Zura Bio (ZURA)Zura BioConference / presentation

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 31, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today

Related news

ACRSAclaris Therapeutics2026-09-03 12:00 EST

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

GPCRStructure Therapeutics2026-11-04 12:30 EST

Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference

SABSSAB Biotherapeutics2026-10-14 12:30 EST

SAB BIO to Participate in Chardan 10th Annual Healthcare Conference

XFORX4 Pharmaceuticals2026-09-09 11:00 EST

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

KNSAKiniksa2026-09-04 20:01 EST

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

HCMHUTCHMED2026-10-27 00:00 EST

Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

GRIGRI Bio2026-08-27 14:01 EST

GRI Bio Featured in "Why Now" On-Demand Video Webcast

ZURAZura Bio2026-10-27 22:00 EST

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IFRXInflarx NV2026-10-22 16:00 EST

InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026

STTKShattuck Labs2026-10-13 12:00 EST

Shattuck Labs Announces Two Poster Presentations at UEG Week 2026

View all latest news

Zura Bio

Autoimmune and Inflammatory Diseases Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules. Tibulizumab Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell...

Recent company news

ZURAZura Bio2026-10-27 22:00 EST

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZURAZura Bio2026-10-27 11:30 EST

Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates

ZURAZura Bio2026-08-31 20:30 EST

Zura Bio to Participate in the Cantor Global Healthcare Conference

ZURAZura Bio2026-08-21 23:57 EST

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZURAZura Bio2026-08-11 11:30 EST

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

Stock data

Close
3.72 USD
Market cap
389.01M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States